How profitable is Alkermes plc (ALKS)?

In FY 2025 (10-K), ALKS converted $1.5B of revenue into a 86.7% gross margin, 17.2% operating margin, and $480.3M in free cash flow (32.5% FCF margin).

Stock Ratings / Health Care / ALKS / financials

AXSM (35) ABVX (54) AMRX (71) KNSA (71) ⌘ Pro Terminal →

Alkermes plc (ALKS) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$44.89 -0.99% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $44.92

Alkermes plc (ALKS) earns a Roarable Rating of B+ (Buy) with 78/100 RQD Confidence. High-quality cash engine (86.7% gross margin, 14% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B+ • BUY Cap $7.61B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ALKS Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ALKS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Alkermes plc (NASDAQ: ALKS) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 78/100 at a spot price of $44.89 (-0.99% 1D, market cap $7.61B). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 14/20, SEC Balance-Sheet Forensics 15/20, FRED Macro Regime Fit 16/20, and Executive Insider Alignment 16/20. Across 1015 tracked Health Care issuers, ALKS ranks #22 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ALKS compare to AXSM and ABVX in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ALKS carries a Roarable B+ (78/100 RQD), trailing P/E of 31.5x, gross margin of 86.7%, and ROIC of 14.0%. By comparison, AXSM (Axsome Therapeutics Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -21.9%, cap $7.57B) and ABVX (Abivax SA) posts a D+ grade (54/100 RQD, P/E 32.8x, ROIC 9.9%, cap $7.56B). Among the 5-stock peer group, ALKS leads on earnings multiple (31.5x) while AMRX leads on capital efficiency (14.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ALKS?

▼

Per ALKS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001520262), Alkermes plc generated $1.48B in revenue (-5.2% YoY), $241.7M in net income, and $480.3M in free cash flow against $2.49B in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (86.7% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $44.92 (+0.06%)🧬 Cannibal Buyback (-2.36% YoY Shares)⚙️ Cash Engine: 17/20 (A-) • 32.5% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 78/100 (B+) historically ranked in the Top 10% of excess returns over the next 90 days (+7.9% avg 90D alpha vs SPY • 70.6% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERBUY • B+

3-of-3 Quant Analysts Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw B+ · Rk B+

Each axis scored 0–20

12M PRICE TARGET CONE+9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ALKS)Realized 20D OHLCV Swing Band: ±6.4%

Deterministic 5-Pillar Attribution (78/100 Composite)

🔍 WHY ALKS SCORES 78/100 (B+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+17/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 32.5% FCF Margin ($480.3M FCF) & 86.7% Gross Margin

▲ #2 Bullish Driver: Macro Regime Fit+16/20 pts (21% of score)

FRED Regime × Technicals: 62% of 52W Range • RSI-14 at 61 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: Whale & Options Positioning14/20 pts (-6 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-6 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B$39.08+11.3% Next Q

Q2 (-2Q)

Grade B$43.48+4.1% Next Q

Q3 (-1Q)

Grade B+$45.25-0.8% Next Q

Current

Grade B+$44.89+7.9% Hist 90D α

Trajectory: B (70) → B+ (78)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the ALKS Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 78/100 (B+) score, ALKS faces multiple-compression risk if 31.5x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.36% YoY Shares) — any gross margin slip below 84.2% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($43.85) or 200D SMA ($40.68) invalidates the momentum regime and cuts Target Base ($48.93) toward Bear Floor ($36.81).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ALKS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ALKS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 78%NO 22%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How ALKS Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$480.3M (32.5% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $1.66B

FY24

Rev $1.56B

FY25

Rev $1.48B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$1.48B	86.7%	17.2%	$241.7M	$480.3M	14%
FY 2024	$1.56B	84.2%	27%	$367.1M	$405.6M	23.1%
FY 2023	$1.66B	86.7%	24.9%	$355.8M	$326.5M	12.9%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ALKS)

✓Walkthrough of ALKS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ALKS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +31.37%⚡ TESTING RESISTANCE

2026-11-03O $45.37H $45.37L $44.89C $44.89VOL 1.11M

RES: $45.92SUP: $35.11SMA50: $43.85SMA200: $40.68

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ALKS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ALKS Butterfly Map → + Track ALKS →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

24.3%/yr Implied 5Y Growth

vs. -5.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ALKS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ALKS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ALKS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ALKS)

Health Care Rank #22 of 1015 ⚔️ AXSM vs ALKS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ALKS vs. AXSM, ABVX, AMRX, KNSA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Alkermes plc (ALKS) ranks #22 by composite RQD confidence (78/100, grade B+) and #126 by equity capitalization ($7.61B). Within this direct 5-issuer industry benchmark cohort, ALKS leads on earnings valuation at 31.5x trailing P/E, while AMRX leads on capital efficiency and profitability with 14.1% ROIC and 36.9% gross margin. ALKS currently leads its immediate peer cohort in composite quantitative strength at 78/100 (B+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ALKS ACTIVE Alkermes plc	B+	78/100	31.5x	86.7%	14.0%	-0.99%	$7.61B	Benchmark Subject
AXSM Axsome Therapeutics Inc.	D-	35/100	—	—	-21.9%	-5.83%	$7.57B	/axsm-vs-alks →
ABVX Abivax SA	D+	54/100	32.8x	—	9.9%	-1.94%	$7.56B	/abvx-vs-alks →
AMRX Amneal Pharmaceuticals Inc.	B-	71/100	103.2x	36.9%	14.1%	-4.97%	$7.49B	/amrx-vs-alks →
KNSA Kiniksa Pharmaceuticals International plc (Class A)	B-	71/100	129.9x	88.5%	9.9%	-1.56%	$7.25B	/knsa-vs-alks →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001520262 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Alkermes plc (ALKS) reported GAAP revenue of $1.48B (-5.2% vs. FY2024 revenue of $1.56B , and -11.3% cumulative change since FY2023) , GAAP net income of $241.7M, operating cash flow of $520.8M, and free cash flow of $480.3M (+18.4% YoY). On the balance sheet, ALKS closed FY2025 with $2.49B in total assets against $0 in total debt (Altman Z-Score: 8.03, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$1.48B	$241.7M	$520.8M	$480.3M	$2.49B	$0
FY2024 (FY)	2024-12-31	$1.56B	$367.1M	$439.1M	$405.6M	$2.06B	$265.8M
FY2023 (FY)	2023-12-31	$1.66B	$355.8M	$401.4M	$326.5M	$4.19B	$979.6M

3. ALKS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ALKS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ALKS compare to AXSM and ABVX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ALKS?

Where is ALKS trading relative to its 50-day, 200-day, and 52-week technical levels?

ALKS last traded at $44.89 (-0.99% on volume of 2,162,831 shares), positioning the stock +2.37% above its 50-day simple moving average ($43.85) and +10.35% above its 200-day simple moving average ($40.68). Across its 52-week range of $27.00 to $55.67, ALKS sits at the 62.4% percentile with a 14-day RSI of 61.0 (BULLISH MOMENTUM) and an implied next-earnings move of ±6.4% ($42.02 to $47.76).

Direct Sub-Reports: ALKS RQD Cockpit ALKS 12M Forecast ALKS Earnings & Move ALKS Dividends & DRIP ALKS Insiders & 13F ALKS Whale Options ALKS Profit Sankey ALKS News & Why

ROARABLE RATING BRIEF • RQD 78/100 (B+) ✓ SEC XBRL & RQD VERIFIED

ALKS — Alkermes plc: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Alkermes plc (ALKS) earns a live Roarable RQD composite score of 78/100, corresponding to a B+ letter grade (Roarable Buy) at a spot price of $44.89 (-0.99% 1D, market capitalization $7.61B).

Fundamental Cash Engine (17/20): Anchored by return on invested capital (ROIC) of 14.0%, gross margin of 86.7%, operating margin of 17.2%, and free cash flow yield of 6.31%.
Whale 13F & Options Flow (14/20) + Insider Conviction (16/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (16/20) + Forensic Balance Sheet (15/20): Incorporates a 1.05x equity beta, Altman Z-Score of 8.03, Piotroski F-Score of 7/9, and Debt/Equity of 0.00x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Alkermes plc (ALKS) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. Its market capitalization is $7.6B, per the market data. Gross margin of 86.7% per the market data indicates a high-margin revenue base.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Alkermes plc (ALKS) reported $1.48B in annual revenue (up from $1.56B in FY2024, -5.2% YoY) and $241.7M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.66B revenue, $355.8M net income) through FY2025, ALKS scaled operating cash flow to $520.8M and free cash flow to $480.3M, backed by $2.49B in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (B+ • RQD 78/100): Strong cash generator (86.7% gross margin)—profits are backed by real money, not accounting tricks. Company leadership has skin in the game with net positive insider conviction. With Fundamental Cash Engine at 17/20 and Institutional Whale Flow at 14/20, sustained execution supports upside toward the upper end of the $27.00 – $55.67 52-week range.
🐻 Primary Bear Case & Valuation Risk: Broader market pullbacks can still drag down strong stocks in the short run. Investors must weigh 31.5x trailing P/E and 25.1x EV/EBITDA against 17.2% operating margins and a 1.05x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), ALKS carries a macro regime beta of 1.05 and gross margin of 86.7%.

Key Question #1: Can ALKS sustain or expand its 17.2% operating margin and 14.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $1.48B and free cash flow of $480.3M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is ALKS's 29.3x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.05x)?

ALKS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Alkermes plc (ALKS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ALKS Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

Alkermes plc (ALKS) Stock Price, News, Quote & History

Yahoo! Finance Canada report covering Alkermes plc (ALKS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 1d ago

Alkermes reinstated Buy at Truist on narcolepsy opportunity

Seeking Alpha report covering Alkermes plc (ALKS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Earnings Preview: Alkermes (ALKS) Q3 Earnings Expected to Decline

Yahoo Finance report covering Alkermes plc (ALKS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall Street • 1d ago

Sleep Data Might Change The Case For Investing In Alkermes Stock (ALKS)

Simply Wall Street report covering Alkermes plc (ALKS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

About 180 adults are expected to take part in a study of an experimental add-on depression treatment.

Stock Titan report covering Alkermes plc (ALKS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Alkermes (ALKS) Holds To Its Narrative, Is The Pullback A Buying Opportunity?

Yahoo Finance report covering Alkermes plc (ALKS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 2d ago

Alkermes (ALKS) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $ALKS

MarketBeat report covering Alkermes plc (ALKS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 2d ago

Alkermes (NasdaqGS:ALKS) Stock Forecast & Analyst Predictions

Simply Wall St report covering Alkermes plc (ALKS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ALKS Bull vs. Bear Conversation Board — What's Your Call at $44.89?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ALKS 🐻 33% BEARISH CONVICTION

SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $58.49 (+29.0%)

📌 Pinned Debate

Free cash flow rose to $480.3M in FY 2025 while debt fell to $0.0M, supported by a 14% ROIC and an Altman Z of 8.03.

The street is overcomplicating Alkermes plc (ALKS). Free cash flow rose to $480.3M in FY 2025 while debt fell to $0.0M, supported by a 14% ROIC and an Altman Z of 8.03.. With an RQD score of 78/100 (B+) and Forensic Balance Sheet at 15/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $48.97.

ArenaChamp_24 🐂 BULL

@ForensicBear Fair point on 31.5x trailing P/E, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (86.7%) holds, EPS grows into the multiple faster than bears think.

FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $38.99 (-14.0%)

Spot @ $45.34

Revenue declined from $1.66B in FY 2023 to $1.48B in FY 2025 and Q3 earnings are expected to decline, at a trailing P/E of 31.5.

Careful chasing ALKS at $45.34. Revenue declined from $1.66B in FY 2023 to $1.48B in FY 2025 and Q3 earnings are expected to decline, at a trailing P/E of 31.5.. Gross margin is 86.7%, but operating margin is 17.2%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $38.99 on multiple compression.